HC Wainwright & Co. reiterates Buy rating on Neurogene, $65 price target

What happened

HC Wainwright & Co. repeated its Buy rating on Neurogene stock and kept a $65.00 price target. The firm said this target means 140.8% upside from the October 27 close of $26.99.

Confirmed

Global impact / market context

A repeated Buy rating with a target far above the last close signals that this analyst still expects strong gains from Neurogene. The note cites promising NGN-401 data for Rett syndrome, which could support investor confidence in approval prospects.

Analyst inference

Neurogene's shares trade well below the analyst target, so the note frames the stock as beaten down relative to expected drug potential. The cited trial data, where 80% of participants met the composite endpoint, is the main support for that more optimistic view.

Analyst inference

What to watch

1. Watch whether Neurogene reports further NGN-401 trial results, since the analyst note cites 80% of participants meeting the composite endpoint, a combined success measure, as a positive signal. Confirmed
2. Track whether other analysts change their ratings or price targets on Neurogene, because a wider gap between analyst views and the market price could shift investor positioning. Proposed
3. Watch Neurogene's spending on developing NGN-401 for Rett syndrome, since rising costs for trials could affect how much cash the company has available. Analyst inference

Evidence

• Original source link unavailable